Frank Glavin

ProterixBio, Inc. supplies novel protein measurement technology. It manufactures and markets the ViBE platform, enabling highly sensitive, automated acoustic immunoassays to accelerate drug discovery, development and production of biological and pharmaceutical products. The company was founded by Edward F. Crawley and Mark Lundstrom in 2002 and is headquartered in Billerica, MA.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA.

HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA.

DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX.

Atreaon, Inc. develops proteins for diseases treatment. It operates as a pharmaceutical company that develops medicines for the treatment of arthritis. The company was founded on December 19, 2011 and is headquartered in Newton, MA.

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

LumiCyte, Inc. provides biotechnology services and offers biochips and information products to the pharmaceutical and biotechnology companies. The company also designs, manufactures, and distributes STS MALDI chips for mass spectrometry analysis of proteins and peptides. Its products are used for the identification and analysis of markers involved in disease processes. The company was founded by T. William Hutchens in 2003 and is headquartered in Fremont, CA

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Advanced Cell Diagnostics, Inc. operates as a biotechnology company. It specializes in the emerging field of molecular pathology and developing cell- and tissue-based diagnostic tests for personalized medicine. The company was founded by Lou Yuling and Steve Chan in 2006 and is headquartered in Newark, CA.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Masters Pharmaceuticals Ltd. provides global healthcare solutions. It distributes prescription and OTC drugs, medical devices and supplies. The firm offers acetylcysteine, aciclovir, amiloride hcl, amitriptyline, baclofen and budesonide products. It supplies advanced medicines to hospitals, pharmacists, clinics and Governments. The company was founded by Suzad Masters and Zulf Masters in 1984 and is headquartered in Elstree, the United Kingdom.

Synchroneuron, Inc. develops therapies for tardive dyskinesia (TD) and other neuropsychiatric disorders. It offers a novel treatment for movement disorders, utilizing a drug with simultaneous effects on excitatory and inhibitory neurotransmission. The company was founded by Kei-Lai L. Fong, William D. Kerns, Marc R. Cote and Barry S. Fogel in 2011 and is headquartered in Newton, MA.

Adjuvance Technologies, Inc.is a biopharmaceutical company. The company was founded by Jeffrey Gardner and is headquartered in Lincoln, NE.

Cognoa, Inc. offers a mobile application and proprietary algorithm to enable early detection of autism. The firm is a consumer healthcare company that?s changing how parents assess and support their child?s development. The company was founded by Dennis Wall and Brent Vaughan and is headquartered in Palo Alto, CA.

Artugen Therapeutics Ltd. develops precision treatments for infections. The company was founded in 2015 and is headquartered in Concord, MA.

K-Gen, Inc. is an American biotechnology company. The private company is based in San Francisco.

TAU Ventures Ltd (TAU Ventures) is a venture capital subsidiary of Tel-Aviv University founded in 2017 by Behzad Kianmahd. The firm is headquartered in Tel Aviv, Israel.

VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.

Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA.